Phenylpiracetam (Phenotropil)
Phenylpiracetam fits rare-use stimulant racetam scenarios; Nick's cited range is 100-200 mg in the morning, while Malykh 2010 supports only broad racetam context. Tolerance, sleep disruption, and athlete bans keep the score low.
Phenylpiracetam (Phenotropil) scored 4.6 / 10 (⚠️ Proceed with caution) on the BioHarmony scale as a Substance → Racetam.
What It Is
Phenylpiracetam (Phenotropil) scores 4.6/10 because its strongest case is stimulant-like cognition, reaction time, and environmental-stress tolerance, with weaker support outside that lane. The best read is practical and narrow: match the intervention to readers weighing a potent racetam against legality, sourcing, and sports-rule constraints.
The main evidence anchor is Malykh and Sadaie 2010. WADA Prohibited List adds important context, while PubChem Phenylpiracetam helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that direct clinical evidence is thin, the compound is prohibited in sport, and gray-market sourcing raises trust issues. This report treats Phenylpiracetam as a candidate for specific use cases, not a general wellness shortcut.
Terminology
AMPA: A glutamate receptor family involved in fast excitatory signaling. - CYP1A2: A liver enzyme relevant to caffeine and xanthine metabolism. - ER Stress: Endoplasmic-reticulum stress, a cellular protein-folding stress pathway. - MAO-B: Monoamine oxidase B, an enzyme that breaks down dopamine-related monoamines. - NOAEL: No observed adverse effect level in toxicology work.
UDCA: Ursodeoxycholic acid, the unconjugated parent bile acid of TUDCA. - WADA: World Anti-Doping Agency, relevant for athlete prohibited-list risk.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 100-200 mg, usually single-use or short cycles in anecdotal reports | 100-200 mg, usually single-use or short cycles in anecdotal reports |
Protocols
Conservative research comparison Mixed
- Dose
- 100-200 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
Upside contribution: 1.11
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.3 | 0.575 | |
| Breadth of Benefits | 15% | 2.2 | 0.330 | |
| Evidence Quality | 25% | 1.5 | 0.375 | |
| Speed of Onset | 10% | 3.7 | 0.370 | |
| Durability | 10% | 1.6 | 0.160 | |
| Bioindividuality Upside | 15% | 2.0 | 0.300 | |
| Total | 2.110 |
Upside Rationale
Phenylpiracetam (Phenotropil) scores 4.6/10 because its upside is concentrated in stimulant-like cognition, reaction time, and environmental-stress tolerance. The clearest anchor is racetam-family pharmacology and regulatory context rather than a large modern trial base, so the rating rewards the specific use cases while staying conservative about claims beyond them.
Efficacy (3.2/5.0): Phenylpiracetam earns this efficacy score because the best signals map to stimulant-like cognition, reaction time, and environmental-stress tolerance. Malykh and Sadaie 2010 is the main anchor, while WADA Prohibited List helps define where the signal remains preliminary.
Breadth of Benefits (2.7/5.0): Phenylpiracetam has limited breadth outside its core lane. The report gives more credit where the evidence matches readers weighing a potent racetam against legality, sourcing, and sports-rule constraints, and less where endpoints drift into unrelated systems.
Evidence Quality (2.0/5.0): Phenylpiracetam evidence quality is constrained by sample size, age of the literature, sponsor concentration, or indirect endpoints. Malykh and Sadaie 2010 and PubChem Phenylpiracetam keep the score useful without overstating certainty.
Speed of Onset (4.0/5.0): Phenylpiracetam can produce faster feedback when the intended effect is acute attention, energy, sleep timing, digestion, or performance. That speed helps users judge fit, but it does not replace longer safety follow-up.
Durability (2.1/5.0): Phenylpiracetam durability is moderate to low when continued dosing, training context, sleep timing, diet, or supply quality drives the result. The score rises only when the benefit can be maintained without chasing dose escalation.
Bioindividuality Upside (2.5/5.0): Phenylpiracetam has meaningful bioindividuality because baseline need, medications, caffeine response, training status, liver or bile context, sleep pressure, and tolerance can change the outcome. WADA Prohibited List is useful for defining that context.
Downside contribution: 1.64 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.3 | 0.690 | |
| Side Effect Profile | 15% | 2.4 | 0.360 | |
| Financial Cost | 5% | 2.5 | 0.125 | |
| Time/Effort Burden | 5% | 1.6 | 0.080 | |
| Opportunity Cost | 5% | 2.2 | 0.110 | |
| Dependency / Withdrawal | 15% | 2.7 | 0.405 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 2.220 | |||
| Harm subtotal × 1.4 | 2.667 | |||
| Opportunity subtotal × 1.0 | 0.315 | |||
| Combined downside | 2.982 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.642 |
Downside Rationale
Phenylpiracetam (Phenotropil) downside is driven by direct clinical evidence is thin, the compound is prohibited in sport, and gray-market sourcing raises trust issues. The risk score is highest where user selection, product quality, stimulant load, medical context, or regulation can change the expected result.
Safety (3.0/5.0): Phenylpiracetam safety concerns are manageable for some users and unacceptable for others depending on dose, diagnosis, medication use, and source quality. WADA Prohibited List is the main safety anchor for this dimension.
Side Effects (3.0/5.0): Phenylpiracetam side effects matter because the likely use cases often depend on subjective feel, stimulation, digestion, sleep, or skin response. Malykh and Sadaie 2010 helps frame expected benefits against tolerability.
Interaction Risk (2.8/5.0): Phenylpiracetam interaction risk rises when users combine it with stimulants, sedatives, anticoagulants, liver-active agents, training stress, or disease-specific treatment. The report keeps this dimension separate from general safety.
Supply (3.3/5.0): Phenylpiracetam supply risk reflects labeling accuracy, adulteration, ingredient identity, and whether the market is supplement, prescription, peptide, or gray-market dominated. PubChem Phenylpiracetam is especially relevant when product trust is part of the risk.
Cost (2.5/5.0): Phenylpiracetam cost risk is not only price per serving. It also includes the cost of chasing weak evidence, lab testing, medical monitoring, or replacing simpler options such as sleep, diet, training, or caffeine management.
Regulatory (4.0/5.0): Phenylpiracetam regulatory risk depends on whether the compound is a normal food, a dietary supplement ingredient, a drug, a sport-restricted substance, or a research peptide. This can be the deciding downside for athletes and cautious users.
Bioindividuality Downside (3.1/5.0): Phenylpiracetam bioindividuality downside is meaningful because personal risk can swing with anxiety, sleep timing, pregnancy, age, liver or kidney status, sport testing, CYP metabolism, and baseline deficiency or excess.
Verdict
Phenylpiracetam is a conditional research candidate rather than a universal recommendation. The score is most favorable when the reader's target matches the highest use-case scores, the product source is credible, and the reader can track a concrete outcome before and after use. The score is least favorable when Phenylpiracetam is used to chase vague optimization, replace higher-certainty basics, or stack with overlapping compounds without a clear reason.
✅ Best for: Occasional research-only stimulant comparison where WADA status, sourcing uncertainty, and rapid tolerance are understood. Phenylpiracetam makes the most sense when the reader can define the target outcome in advance, compare Phenylpiracetam with the related reports above, and stop quickly if the result is poor.
❌ Avoid if: Avoid Phenylpiracetam when legal status, athlete testing, medication conflicts, allergy risk, organ disease, pregnancy questions, stimulant sensitivity, or poor sourcing changes the risk picture. Avoid using Phenylpiracetam as a substitute for sleep, nutrition, training, medical care, or well-supported alternatives.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 5.2/10
Score: 5.2/10Phenylpiracetam scores 5.2/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Malykh A. et al. 2010, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Phenylpiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Energy / Fatigue: 5.3/10
Score: 5.3/10Phenylpiracetam scores 5.3/10 for energy because the most plausible benefit is acute perceived energy or stimulant-like activation. The strongest support comes from Malykh A. et al. 2010, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Phenylpiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Reaction Time / Coordination: 5.0/10
Score: 5.0/10Phenylpiracetam scores 5.0/10 for reaction time because the reported benefit is most likely to show up on short-latency cognitive or performance tasks. The strongest support comes from Malykh A. et al. 2010, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Phenylpiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Cold / Heat Tolerance / Hormesis: 5.0/10
Score: 5.0/10Phenylpiracetam scores 5.0/10 for cold heat tolerance because the historical origin story and stimulant profile fit environmental-stress tolerance better than most other nonprimary goals. The strongest support comes from Malykh A. et al. 2010, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Phenylpiracetam is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does Phenylpiracetam actually do?
Phenylpiracetam mainly acts through the biology described in this report, and the best concise source is Malykh A. et al. 2010. Phenylpiracetam should be read as a research-assistance topic rather than a treatment recommendation. That is why the score separates plausible pathways from proven user value.
How much Phenylpiracetam is typically used?
Phenylpiracetam is usually discussed around 100-200 mg, usually single-use or short cycles in anecdotal reports, but dosing depends on context, product quality, and clinician constraints. This report lists research and anecdotal ranges for comparison only. Phenylpiracetam should not be stacked casually with overlapping drugs or stimulants, and higher doses should be treated as a separate risk decision. The safest reading is to compare published ranges with the label and personal tolerance.
What does the human evidence show for Phenylpiracetam?
Phenylpiracetam has an evidence profile led by Malykh A. et al. 2010 and the other sources in the evidence table. Phenylpiracetam receives credit when human outcomes exist and loses credit when the work is small, industry-concentrated, disease-specific, or not independently replicated. That is why a popular community use can still receive a modest score when the direct clinical literature is thin.
Is Phenylpiracetam safe long term?
Phenylpiracetam looks safer when dose, source quality, medication conflicts, and stop criteria are handled conservatively. The long-term safety answer is weaker when human follow-up is short, when products are unapproved drugs, or when stimulant effects can affect sleep and cardiovascular comfort. Phenylpiracetam earns a better safety rating only where the evidence base includes ordinary-use tolerability and clear reversibility.
Who should avoid Phenylpiracetam?
Phenylpiracetam should be avoided by readers with relevant medication conflicts, pregnancy questions, severe organ disease, allergy risk, or athlete testing exposure when those concerns apply. Phenylpiracetam also deserves caution when the supply chain is unclear or when the main goal could be met by better-studied options. The report frames these as research guardrails, not individualized medical instructions.
How fast does Phenylpiracetam work?
Phenylpiracetam may feel acute when the mechanism is stimulant-like, but disease or recovery outcomes usually need longer observation. The timeline in this report separates same-day subjective effects from delayed biomarkers and functional changes. Phenylpiracetam should be judged with a preplanned outcome, because vague improvement tracking can make short-lived arousal feel more useful than it is.
How is Phenylpiracetam different from nearby alternatives?
Phenylpiracetam differs from nearby alternatives by mechanism, evidence quality, legality, and product reliability. The related reports linked in the verdict help compare Phenylpiracetam with better-known options before treating the category as interchangeable. A close alternative may have lower subjective novelty but better replication, easier sourcing, or fewer interaction problems, which matters for the final score.
What would make the Phenylpiracetam score change?
Phenylpiracetam would score higher with larger independent trials, longer safety follow-up, clearer dosing, and direct evidence for the main use cases. Phenylpiracetam would score lower if safety signals strengthen, product quality worsens, or better alternatives cover the same goal with less uncertainty. The score is therefore a snapshot of current evidence, not a permanent verdict.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Phenylpiracetam could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Phenylpiracetam could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 5.8 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 4.6 / 10 ⚠️ Caution |
| New safety, sourcing, regulatory, or replication concerns appear. | 3.4 / 10 🚫 Skip |
BioHarmony Engine v1.0
Key Evidence Sources
- Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- Wikidata entity Q418101. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- Dietary Supplements. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- ClinicalTrials registry. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- PubChem compound database. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- World Anti-Doping Agency prohibited list. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
- NIH Office of Dietary Supplements. Reviewed in 2026 as clinical or mechanistic background; sample, year, and endpoint directness shape the confidence rating.
- MedlinePlus herbs and supplements. Reviewed in 2026 for citation integrity; useful for mechanism or outcome context but not treated as universal proof.
- PubMed biomedical literature database. Reviewed in 2026 as a primary evidence source; study design, year, and endpoint context are used to bound the report claim.
- Cochrane Library evidence database. Reviewed in 2026 for study design and population fit; supports a specific endpoint rather than broad wellness claims.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Malykh 2010: Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
Pre-RCT-Era Pharmacology and Use
Citations: Piracetam and piracetam-like drugs: from basic science to novel cli..., World Anti-Doping Agency prohibited list, PubChem compound database
Traditional Medicine Systems
Citations: Piracetam and piracetam-like drugs: from basic science to novel cli..., World Anti-Doping Agency prohibited list, PubChem compound database
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Blood Pressure Baseline (pre-protocol)
- Resting Heart Rate During | Expected Watch
- Sleep Duration During | Expected Down
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Drive During | Expected Up | Primary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Focus Intensity Scale 1-5 | During | Expected Up
- Irritability Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Chest pain, palpitations, or severe anxiety
- Athlete exposure due to WADA prohibited status
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.110 − 1.642 = -0.532
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.532 / 7) × 5 = 4.6 / 10
Further learning
65+ Nootropic Ingredients I’ve Supplemented (Rated & Reviewed)
I've tested all kinds of nootropic ingredients & brain-boosting supplements. Here's a simple rundown, my personal ratings and mini review, and practical uses of…
Unconventional Ways to Power Up Your Brain & Perform Like an Elite Athlete
Did you know you could optimize your brain & body performance using nootropics safely & effectively? We discuss using substances like caffeine, dynamine &…
